- Home
- INCY vs MANH Comparison
INCY vs MANH Comparison
Compare INCY & MANH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- MANH
- Stock Information
- Founded
- INCY 1991
- MANH 1990
- Country
- INCY United States
- MANH United States
- Employees
- INCY N/A
- MANH N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- MANH Computer Software: Prepackaged Software
- Sector
- INCY Health Care
- MANH Technology
- Exchange
- INCY Nasdaq
- MANH Nasdaq
- Market Cap
- INCY 13.0B
- MANH 13.0B
- IPO Year
- INCY 1993
- MANH 1998
- Fundamental
- Price
- INCY $86.64
- MANH $215.31
- Analyst Decision
- INCY Buy
- MANH Buy
- Analyst Count
- INCY 20
- MANH 9
- Target Price
- INCY $80.31
- MANH $221.25
- AVG Volume (30 Days)
- INCY 1.7M
- MANH 489.0K
- Earning Date
- INCY 10-28-2025
- MANH 10-21-2025
- Dividend Yield
- INCY N/A
- MANH N/A
- EPS Growth
- INCY 900.04
- MANH 9.17
- EPS
- INCY 4.37
- MANH 3.58
- Revenue
- INCY $4,584,996,000.00
- MANH $1,057,690,000.00
- Revenue This Year
- INCY $16.26
- MANH $5.15
- Revenue Next Year
- INCY $11.07
- MANH $6.66
- P/E Ratio
- INCY $19.84
- MANH $60.13
- Revenue Growth
- INCY 18.87
- MANH 6.13
- 52 Week Low
- INCY $53.56
- MANH $140.81
- 52 Week High
- INCY $87.99
- MANH $312.60
- Technical
- Relative Strength Index (RSI)
- INCY 64.89
- MANH 53.18
- Support Level
- INCY $83.41
- MANH $202.26
- Resistance Level
- INCY $87.99
- MANH $220.00
- Average True Range (ATR)
- INCY 1.68
- MANH 4.86
- MACD
- INCY -0.37
- MANH -0.83
- Stochastic Oscillator
- INCY 70.52
- MANH 71.19
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About MANH Manhattan Associates Inc.
Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers around the world.